These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 27129929)

  • 1. Genetic prediction of the effectiveness of biologics for psoriasis treatment.
    Nishikawa R; Nagai H; Bito T; Ikeda T; Horikawa T; Adachi A; Matsubara T; Nishigori C
    J Dermatol; 2016 Nov; 43(11):1273-1277. PubMed ID: 27129929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs.
    Ovejero-Benito MC; Muñoz-Aceituno E; Sabador D; Almoguera B; Prieto-Pérez R; Hakonarson H; Coto-Segura P; Carretero G; Reolid A; Llamas-Velasco M; Abad-Santos F; Daudén E
    Exp Dermatol; 2020 Dec; 29(12):1225-1232. PubMed ID: 33058233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics.
    Asahina A; Umezawa Y; Yanaba K; Nakagawa H
    J Dermatol; 2016 Jul; 43(7):779-84. PubMed ID: 26704718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.
    Ovejero-Benito MC; Prieto-Pérez R; Llamas-Velasco M; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Talegón M; Cabaleiro T; Daudén E; Abad-Santos F
    Pharmacogenomics; 2018 Jan; 19(1):7-16. PubMed ID: 29192552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study.
    Ara-Martín M; Pinto PH; Pascual-Salcedo D
    J Dermatolog Treat; 2017 Nov; 28(7):606-612. PubMed ID: 28274164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary artery involvement in Behçet׳s syndrome: Effects of anti-Tnf treatment.
    Hamuryudan V; Seyahi E; Ugurlu S; Melikoglu M; Hatemi G; Ozguler Y; Akman C; Tuzun H; Yurdakul S; Yazici H
    Semin Arthritis Rheum; 2015 Dec; 45(3):369-73. PubMed ID: 26190564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
    Kui R; Gál B; Gaál M; Kiss M; Kemény L; Gyulai R
    J Dermatol; 2016 Sep; 43(9):1018-23. PubMed ID: 26892625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis.
    Julià A; Fernandez-Nebro A; Blanco F; Ortiz A; Cañete JD; Maymó J; Alperi-López M; Fernández-Gutierrez B; Olivè A; Corominas H; Erra A; Acosta-Colman I; Alonso A; López-Lasanta M; Tortosa R; Tornero J; Marsal S
    Pharmacogenomics J; 2016 Apr; 16(2):147-50. PubMed ID: 25896534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL17RA gene variants and anti-TNF response among psoriasis patients.
    Batalla A; Coto E; Gómez J; Eirís N; González-Fernández D; Gómez-De Castro C; Daudén E; Llamas-Velasco M; Prieto-Perez R; Abad-Santos F; Carretero G; García FS; Godoy YB; Cardo LF; Alonso B; Iglesias S; Coto-Segura P
    Pharmacogenomics J; 2018 Jan; 18(1):76-80. PubMed ID: 27670766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population.
    Vasilopoulos Y; Manolika M; Zafiriou E; Sarafidou T; Bagiatis V; Krüger-Krasagaki S; Tosca A; Patsatsi A; Sotiriadis D; Mamuris Z; Roussaki-Schulze A
    Mol Diagn Ther; 2012 Feb; 16(1):29-34. PubMed ID: 22111980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent.
    Yamauchi PS; Bissonnette R; Teixeira HD; Valdecantos WC
    J Am Acad Dermatol; 2016 Sep; 75(3):612-618.e6. PubMed ID: 27061047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring of patients with psoriasis during tumour necrosis factor (TNF)-α antagonist treatment using a novel interleukin-8 reporter cell line.
    Kimura Y; Shimada-Omori R; Takahashi T; Tsuchiyama K; Kusakari Y; Yamasaki K; Nishikawa R; Nishigori C; Aiba S
    Br J Dermatol; 2016 Nov; 175(5):979-987. PubMed ID: 27155194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association of TNFA, TNFRSF1B and TNFAIP3 gene polymorphisms with response to anti-tumor necrosis factor therapy in Japanese patients with psoriasis.
    Ito M; Hirota T; Momose M; Ito T; Umezawa Y; Fukuchi O; Asahina A; Nakagawa H; Tamari M; Saeki H
    J Dermatol; 2020 Apr; 47(4):e110-e111. PubMed ID: 31872456
    [No Abstract]   [Full Text] [Related]  

  • 16. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
    Gallo E; Cabaleiro T; Román M; Solano-López G; Abad-Santos F; García-Díez A; Daudén E
    Br J Dermatol; 2013 Oct; 169(4):819-29. PubMed ID: 23662788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic response modifiers and pediatric psoriasis.
    Bellodi Schmidt F; Shah KN
    Pediatr Dermatol; 2015; 32(3):303-20. PubMed ID: 25727936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.
    Tan E; Baker C; Foley P
    Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.
    Bissonnette R; Maari C; Barber K; Lynde CW; Vender R
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1576-81. PubMed ID: 25600828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.